The first
The only
2nd-generation
IV antihistamine1

African American woman smiling African American woman smiling

Quzyttir is indicated for the treatment of acute urticaria1

Line drawing of bar graphic representing efficacy
Efficacy
in acute urticaria demonstrated in a phase 3 study comparing Quzyttir to IV diphenhydramine (DPH) as an active control1*
Clock with attached arrow pointing right to represent onset and duration of action
Onset and duration of action
Time to Cmax:
Quzyttir 5 mg: 3.6 minutes1
Quzyttir 10 mg: 1.8 minutes1
Drug activity persists for at least 24 hours1
Graphic of senior citizen with cane and child without cane
Special populations
Use in pediatric and geriatric patients
Graphic of 3 pills and triangle with exclamation point inside
Drug interactions
No clinically significant drug interactions were observed in studies with oral cetirizine1
  • *Study design: Randomized, active-controlled, double-blind, single-dose, multicenter (US and Canada), parallel-group trial in 262 adults presenting to emergency departments (EDs) or urgent care centers with acute urticaria with or without other diseases, including patients with concomitant angioedema, and with or without history of prior allergic reaction. The primary efficacy endpoint was the change from baseline in patient-rated pruritus score assessed 2 hours post-treatment. The trial was noninferiority design with the pre-specified noninferiority margin of 0.50 for the difference between treatment groups.
For more information or to request a rep visit, call 1-8‍66-QUZYTTIR